
Stocks Market
Laprophan Receives AMMC Approval for Casablanca IPO to Fund Expansion
Laprophan has secured the AMMC’s green light for a public offering on the Casablanca Stock Exchange, aiming to raise up to MAD 2.22 billion. The IPO combines a new share issue of MAD 1.40 billion and the sale of existing shares worth MAD 0.82 billion, representing 37.64 % of the company’s capital. The funds will support the firm’s ongoing external‑growth strategy, recent acquisitions (including Rivopharm in Switzerland and the pending purchase of Polymédic), and reinforce its financial structure and industrial development. The offering is priced at MAD 341 per share and will be available from 9 to 17 November 2026.
Listen to this article
Unlock audio versions of premium articles and more with a Pro subscription.
Overview
Laprophan has received the AMMC’s authorization (reference VI/EM/033/2026) to launch an initial public offering on the Casablanca Stock Exchange. The total maximum proceeds of the IPO are MAD 2,222,535,700, aimed at financing the company’s current development and external growth, supporting recent acquisitions and strengthening its financial structure.
IPO Structure
- New share issue: A public subscription increase of MAD 1,399,975,500 (including issue premium) will be offered to the market.
- Secondary offering: MC IV Pharma and MC IV Morocco will sell 2,412,200 existing shares for up to MAD 822,560,200.
After the operation, the shares offered to the public will represent 37.64 % of the capital and voting rights. The price per share is set at MAD 341.
Strategic Objectives
The capital raised will fund Laprophan’s external‑growth plan, which includes the recent acquisition of a 60 % stake in Swiss group Rivopharm and the pending acquisition of Corporate Investment Holding (parent of Polymédic), subject to competition authority approval. It will also reinforce the firm’s integrated multi‑pole model, spanning R&D, manufacturing, and distribution across Morocco and Switzerland.
Industrial Footprint
Laprophan operates four production sites totalling ~76,500 m²:
- Casablanca historic site – ~90 million UVC/year capacity.
- Aïn El Aouda – Bêtalactamines (Amanys Pharma) – solid oral antibiotics, scaling to 25 million UVC/year by 2027.
- Aïn El Aouda – new sterile injectables unit – ~30 million UVC/year (commissioning 2027).
- Manno (Rivopharm, Switzerland) – ~35 million UVC/year, certified Swissmedic, EU‑GMP and US‑FDA.
Total production capacity exceeds 180 million UVC annually, backed by an automated logistics centre.
Portfolio & Market Presence
The group holds over 1,300 market authorisations across 15 therapeutic areas, including generics, proprietary brands (four patented products), and specialty hospital products via Amanys Pharma. Internationally, it operates through subsidiaries in Germany, the UK and Lithuania, serving more than 50 countries.
Financial Calendar
Subscription period: 9 – 17 November 2026.
Prospectus (AMMC‑approved) is available free of charge on the websites of the AMMC, the Casablanca Stock Exchange, and Laprophan (www.laprophan.com). CFG Finance acts as global coordinator and financial adviser.